Clinical Report: Targeting RAS Pathways in Non-Small Cell Lung Cancer

Overview

The review discusses the emergence of direct KRAS-targeted therapies for non-small cell lung cancer (NSCLC), particularly focusing on KRAS G12C inhibitors. It highlights the rapid development of various KRAS-targeting molecules.

Background

Oncogenic KRAS mutations are prevalent in NSCLC, occurring in up to 30% of patients, making them a critical target for therapeutic intervention. Recent advancements have led to the development of covalent KRAS G12C inhibitors.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

• KRAS mutations are the most common driver event in NSCLC.
• Direct targeting of KRAS has seen advancements, particularly with G12C inhibitors.
• Multiple chemotypes for KRAS targeting are in clinical testing, extending beyond G12C alleles.
• New classifications for KRAS-targeting molecules include pan-KRAS and pan-RAS inhibitors.
• Combination therapies with conventional and novel treatments are being explored for KRAS-targeted strategies.

Clinical Implications

Clinicians should stay informed about ongoing trials and emerging therapies.

Conclusion

The review discusses the evolution of KRAS-targeted therapies in NSCLC.

Related Resources & Content

1. ASCO Living Guideline, Version 2025.1, Journal of Clinical Oncology -- Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations
2. FDA -- FDA approvals of Lumakras (sotorasib) for patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer
3. The ASCO Post — Targeting KRAS Mutations in Lung Cancer: No Longer Impossible
4. fox chase cancer center — Aiming to Refine NSCLC Targeted Therapy
5. The ASCO Post — Expert Point of View: Mark Awad, MD, PhD
6. The ASCO Post — Selumetinib/Docetaxel Shows Promising Activity in Previously Treated KRAS-mutant Non-Small Cell Lung Cancer
7. Targeting KRAS Mutations in Lung Cancer: No Longer Impossible
8. Aiming to Refine NSCLC Targeted Therapy
9. Expert Point of View: Mark Awad, MD, PhD
10. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1 | Journal of Clinical Oncology
11. FDA D.I.S.C.O. Burst Edition: FDA approvals of Lumakras (sotorasib) for patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer, and Truseltiq (infigratinib) for unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement | FDA
12. CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC | IASLC